DeHovitz J A, Kovacs A, Feldman J G, Anastos K, Young M, Cohen M, Gange S J, Melnick S, Greenblatt R M
State University of New York, Downstate Medical Center, Brooklyn, NY 11201, USA.
J Infect Dis. 2000 Nov;182(5):1527-30. doi: 10.1086/315875. Epub 2000 Sep 27.
The relationship between the pattern of virus load response to highly active antiretroviral therapy (HAART) and CD4 lymphocyte response was assessed in a cohort of 249 human immunodeficiency virus (HIV) type 1-infected women at 3 times: 1 before and 2 after initiation of therapy, with follow-up of 6-12 months. Patients with a durable response to HAART (i.e., >1 log decrease in HIV-1 RNA sustained for the study periods) had a continuous and significant increase in CD4 cell counts over time, whereas those with no response (<0.5 log decrease in HIV-1 RNA) had a slight decline. Patients with a mixed response (initial decrease >1 log, followed by a subsequent decrease <0.5 log) had an increase in CD4 cell count, followed by a plateau. The trend in CD4 cell count differed significantly by response to HAART, with those patients who experienced a durable response having significantly higher CD4 cell counts than others.
在一个由249名感染1型人类免疫缺陷病毒（HIV）的女性组成的队列中，分3个时间点评估了高效抗逆转录病毒治疗（HAART）的病毒载量反应模式与CD4淋巴细胞反应之间的关系：治疗开始前1次，治疗开始后2次，随访6至12个月。对HAART有持久反应（即在研究期间HIV-1 RNA持续下降>1 log）的患者，其CD4细胞计数随时间持续且显著增加，而无反应（HIV-1 RNA下降<0.5 log）的患者则略有下降。有混合反应（初始下降>1 log，随后下降<0.5 log）的患者，其CD4细胞计数先增加，随后趋于平稳。CD4细胞计数的趋势因对HAART的反应不同而有显著差异，有持久反应的患者的CD4细胞计数显著高于其他患者。
